Syntara the science explained, page-252

I think because 6302 was demonstrated to have worked, and that acknowledging that had patients had younger scars and been given more than 3-months treatment, we would have seen improvement in the POSAS scores, we will see success ultimately with 6302.

Professor Fiona Wood's comments at the time and since about the 'unprecedented' effects of 6302 leading to changes in scar composition not observed with other treatments, means (to me) that success will come in due course. But biotech does move slowly.

I think SNT seem to have moved forward well concentrating on 5505, letting Professor Wood work away on 6302, and having Parkinsons and MDS on the go also.